Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study

Respiratory Medicine

Volumn 102, Issue 10, 2008, Pages 1371-1378

  Niven, R ^a   Chung, K F ^b   Panahloo, Z ^c   Blogg, M ^c   Ayre, G ^c  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Allergic asthma; Asthma; IgE; Omalizumab

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; OMALIZUMAB; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ANNUAL ASTHMA DETERIORATION RELATED INCIDENT; ARTICLE; BEST STANDARD CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINI ASTHMA QUALITY OF LIFE QUESTIONNAIRE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; WASSERFALLEN SCORE;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; DRUG THERAPY, COMBINATION; EUROPEAN UNION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; LUNG; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 50549102147     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.06.002     Document Type: Article

References (34)

1. Rea H.H., Scragg R., Jackson R., Beaglehole R., Fenwick J., and Sutherland D.C. A case-control study of deaths from asthma. Thorax 41 (1986) 833-839
2. Crane J., Pearce N., Burgess C., Woodman K., Robson B., and Beasley R. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 21 (1992) 737-744
3. Guite H.F., Dundas R., and Burney P.G.J. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax 54 (1999) 301-307
4. Hartert T.V., Speroff T., Togias A., Mitchel Jr. EF., Snowden MS., Dittus RS., et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 89 (2002) 467-473
5. Tough S.C., Hessel P.A., Ruff M., Green F.H., Mitchell I., and Butt J.C. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 35 (1998) 657-665
6. Dolan C.M., Fraher K.E., Bleecker E.R., Borish L., Chipps B., Hayden ML., et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 92 (2004) 32-39
7. Andersson F., and Borg Stahl E. The impact of exacerbations on the asthmatic patient's preference scores. J Asthma 40 (2003) 615-623
8. Juniper E.F., Wisniewski M.E., Cox F.M., Emmett A.H., Nielsen K.E., and O'Bryne P.M. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 23 (2004) 287-291
9. Schmier J., Leidy N.K., and Gower R. Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. J Asthma 40 (2003) 383-393
10. Turk F., Piercy J., and Benford M. The human impact of severe persistent allergic asthma; results of a multinational study. Value Health 9 (2005) A32
11. Antonicelli L., Bucca C., Neri M., De Benedetto F., Sabbatani P., Bonifazi F., et al. Asthma severity and medical resource utilisation. Eur Respir J 23 (2004) 723-729
12. Godard P., Chanez P., Siraudin L., Nicoloyannis N., and Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 19 (2002) 61-67
13. Serra-Batlles J., Plaza V., Morejon E., Comella A., and Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 12 (1998) 1322-1326
14. Turk F., Kay S., and Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Thorax 60 Suppl. II (2005) P21
15. Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA). Available from: (2006). http://www.ginasthma.org
16. Bateman E.D., Boushey H.A., Bousquet J., Busse WW., Clark TJ., Pauwels RA., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
17. Partridge M.R., van der Molen T., Myrseth S.E., and Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 6 (2006) 13
18. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2005) 309-316
19. Ayres J.G., Higgins B., Chilvers E.R., Ayre G., Blogg M., and Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59 (2004) 701-708
20. Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 59 (2004) 709-717
21. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa GD., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001) 184-190
22. Lanier B.Q., Corren J., Lumry W., Liu J., Fowler-Taylor A., and Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91 (2003) 154-159
23. Solèr M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18 (2001) 254-261 (Erratum in: Eur Respir J 2001;18:739-40)
24. Buhl R., Solèr M., Matz J., Townley R., O'Brien J., Noga O., et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 20 (2002) 73-78
25. Holgate S.T., Chuchalin A.G., Hébert J., Lötvall J., Persson GB., Chung KF., et al. Efficacy and tolerability of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34 (2004) 632-638
26. Bousquet J., Cabrera P., Berkman N., Buhl R., Holgate S., Wenzel S., et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60 (2005) 302-308
27. Bousquet J., Rabe K., Humbert M., Chung KF., Berger W., Fox H., et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 101 (2007) 1483-1492
28. Dewilde S., Turk F., Tambour M., and Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 22 (2006) 1765-1766
29. Brown R., Turk F., Dale P., and Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62 (2007) 149-153
30. National Institutes for Health, National Heart, Lung, and Blood Institute. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. NIH Publication no. 97-4051 (1997)
31. Juniper E.F., Guyatt G.H., Cox F.M., Ferrie P.J., and King D.R. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 14 (1999) 32-38
32. Lahdensuo A., Haahtela T., Herrala J., Kava T., Kiviranta K., Kuusisto P., et al. Randomised comparison of guided self management and traditional treatment of asthma over one year. BMJ 312 (1996) 748-752
33. Wasserfallen J.B., Gold K., Schulman K.A., and Baraniuk J.N. Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J Allergy Clin Immunol 100 (1997) 16-22
34. Walker S., Monteil M., Phelan K., Lasserson T.J., and Walters E.H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev (2006 Apr 19) (2):CD003559